Movatterモバイル変換


[0]ホーム

URL:


DK1940447T3 - Behandling af neurodegenrative lidelser - Google Patents

Behandling af neurodegenrative lidelser

Info

Publication number
DK1940447T3
DK1940447T3DK06793581.7TDK06793581TDK1940447T3DK 1940447 T3DK1940447 T3DK 1940447T3DK 06793581 TDK06793581 TDK 06793581TDK 1940447 T3DK1940447 T3DK 1940447T3
Authority
DK
Denmark
Prior art keywords
treatment
neurodegenrative
disorders
neurodegenrative disorders
Prior art date
Application number
DK06793581.7T
Other languages
English (en)
Inventor
Anton Haselbeck
Joerg Huwyler
Michael Jarsch
Frank Herting
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=37622051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1940447(T3)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche
Application grantedgrantedCritical
Publication of DK1940447T3publicationCriticalpatent/DK1940447T3/da

Links

Classifications

Landscapes

DK06793581.7T2005-09-282006-09-18Behandling af neurodegenrative lidelserDK1940447T3 (da)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
EP051089462005-09-28
PCT/EP2006/066438WO2007039436A1 (en)2005-09-282006-09-18Treatment of neurodegenerative disorders

Publications (1)

Publication NumberPublication Date
DK1940447T3true DK1940447T3 (da)2014-01-20

Family

ID=37622051

Family Applications (1)

Application NumberTitlePriority DateFiling Date
DK06793581.7TDK1940447T3 (da)2005-09-282006-09-18Behandling af neurodegenrative lidelser

Country Status (18)

CountryLink
US (2)US20070072795A1 (da)
EP (1)EP1940447B1 (da)
JP (1)JP5096345B2 (da)
KR (1)KR20080038440A (da)
CN (1)CN101277715B (da)
AR (1)AR055654A1 (da)
AU (1)AU2006298826B2 (da)
BR (1)BRPI0616572A2 (da)
CA (1)CA2622609A1 (da)
DK (1)DK1940447T3 (da)
ES (1)ES2445035T3 (da)
IL (1)IL189853A (da)
PL (1)PL1940447T3 (da)
RU (1)RU2467761C2 (da)
SI (1)SI1940447T1 (da)
TW (1)TWI380824B (da)
WO (1)WO2007039436A1 (da)
ZA (1)ZA200802270B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AR067536A1 (es)2007-07-172009-10-14Hoffmann La RocheMetodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
CL2008002053A1 (es)2007-07-172009-05-22Hoffmann La RocheMetodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
RU2515914C1 (ru)*2013-02-122014-05-20Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика"Гибридный белок на основе рекомбинантного эритропоэтина человека, обладающий пролонгированным действием (варианты), и способ его получения
RU2561050C2 (ru)2013-08-282015-08-20Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН)Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера
AR113091A1 (es)*2018-09-272020-01-22Univ Nacional Del LitoralEritropoyetina humana modificada

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US644077A (en)*1898-08-011900-02-27Farbenfabriken Of Elberfeld CompanyAcetyl salicylic acid.
FR2646438B1 (fr)*1989-03-202007-11-02Pasteur InstitutProcede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5641670A (en)*1991-11-051997-06-24Transkaryotic Therapies, Inc.Protein production and protein delivery
US5733761A (en)*1991-11-051998-03-31Transkaryotic Therapies, Inc.Protein production and protein delivery
US5672662A (en)*1995-07-071997-09-30Shearwater Polymers, Inc.Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6703381B1 (en)*1998-08-142004-03-09Nobex CorporationMethods for delivery therapeutic compounds across the blood-brain barrier
HUP0201598A3 (en)*1999-04-132002-10-28Kenneth S Warren Inst OssiningPharmaceutical composition comprising erythropoietin for modulation of excitable tissue function and their use
US6225895B1 (en)*1999-05-262001-05-01Floyd E. Bigelow, Jr.Towed vehicle monitor system
CZ299516B6 (cs)*1999-07-022008-08-20F. Hoffmann-La Roche AgKonjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
DE60109625T3 (de)*2000-05-152017-08-03F. Hoffmann-La Roche AgFlüssige arzneizubereitung enthaltend ein erythropoietin derivat
WO2002003848A2 (en)*2000-07-102002-01-17Naito Albert TMethod for opening the blood-brain barrier
DE10043457A1 (de)*2000-09-042002-03-28Hannelore EhrenreichVerfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
EP1345628B1 (en)*2000-12-202011-04-13F. Hoffmann-La Roche AGConjugates of erythropoietin (epo) with polyethylene glycol (peg)
US6531121B2 (en)*2000-12-292003-03-11The Kenneth S. Warren Institute, Inc.Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en)*2000-12-292010-08-03The Kenneth S. Warren Institute, Inc.Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en)*2000-12-292003-04-17Michael BrinesTissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
AU2003273615B2 (en)*2002-06-112010-07-29Brigham And Women's HospitalNeuroprotective synergy of erythropoietin and insulin-like growth factor
US20040122216A1 (en)*2002-07-012004-06-24Jacob NielsenRecombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
US7459436B2 (en)*2002-11-222008-12-02Hoffmann-La Roche Inc.Treatment of disturbances of iron distribution
US7718363B2 (en)*2003-04-252010-05-18The Kenneth S. Warren Institute, Inc.Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
CA2526096A1 (en)*2003-05-192004-12-29The Kenneth S. Warren Institute, Inc.Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window
DK1696947T3 (da)*2003-12-192014-03-17Hoffmann La RocheAnvendelse af erythropoietin i behandlingen af forstyrrelser af jernfordelingen i kronisk inflammatorisk intestinale sygdomme
DE602006018334D1 (de)*2005-09-282010-12-30Hoffmann La RocheIndol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten

Also Published As

Publication numberPublication date
EP1940447A1 (en)2008-07-09
CN101277715A (zh)2008-10-01
CA2622609A1 (en)2007-04-12
ZA200802270B (en)2009-02-25
TWI380824B (zh)2013-01-01
PL1940447T3 (pl)2014-04-30
BRPI0616572A2 (pt)2009-11-24
AR055654A1 (es)2007-08-29
WO2007039436A1 (en)2007-04-12
AU2006298826A1 (en)2007-04-12
JP5096345B2 (ja)2012-12-12
US20100267632A1 (en)2010-10-21
RU2008116309A (ru)2009-11-10
IL189853A (en)2012-06-28
KR20080038440A (ko)2008-05-06
RU2467761C2 (ru)2012-11-27
AU2006298826B2 (en)2010-04-01
SI1940447T1 (sl)2014-03-31
US20070072795A1 (en)2007-03-29
EP1940447B1 (en)2013-11-27
IL189853A0 (en)2008-11-03
JP2009510008A (ja)2009-03-12
CN101277715B (zh)2013-03-27
TW200727911A (en)2007-08-01
ES2445035T3 (es)2014-02-27

Similar Documents

PublicationPublication DateTitle
DK1890684T3 (da)Behandling af søvn/vågenhedsforstyrrelser
DK1720866T3 (da)Fremgangsmåde
EP1845849A4 (en) EXISCELET FOR THE LEGS
EP1874239A4 (en) HALF-POWERED EXOSCELETT OF LOWER EXTREMITY
DK3403657T3 (da)Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1938528T3 (da)Provision af qos-behandling baseret på flere anmodninger
DK1874781T3 (da)Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK1986633T3 (da)Behandling af duchennes muskeldystrofi
DK1685834T3 (da)Anvendelse af pinolensyre til behandling af obesitet
DK2056807T3 (da)Behandling af inflammatoriske sygdomme
DK1869025T3 (da)Piperazin-substituerede benzothiophener til behandling af mentale lidelser
DK2084151T3 (da)Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
NO20070251A (no)Brønnbehandling
DK1948176T3 (da)Diarylurinstoffer til behandling af pulmonær hypertension
FI20060708L (fi)Hierontalaite
NO20070297A (no)Brønnbehandling
CY2200156T2 (el)Επεξεργασια λυματων
DK1708992T3 (da)Sulfonamidderivater til behandling af sygdomme
DK1962869T3 (da)Behandling af luftvejssygdomme
DK1907374T3 (da)Til behandling af gastrointestinale sygdomme anvendelige benzylpiperazin-derivater
DK2056858T3 (da)Behandling af lungesygdomstilstande
DK1841433T3 (da)Præparat til behandling af lidelser i centralnervesystemet
BRPI0715728A8 (pt)tratamento de distúrbios cartilaginosos
DK2117565T3 (da)Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
EP1937192A4 (en) orthosis

[8]ページ先頭

©2009-2025 Movatter.jp